Pharmacology

September 2015 Vol. 10 No. 9

Author: Amy M. Karch, MS, RN, CNS

Preventable medication errors cost the U.S. healthcare system more than $21 billion annually, according to the National Priorities Partnership and National Quality Forum. This number has risen significantly since the Institute of Medicine published To Err Is Human: Building a Safer Health System in 1999. That report suggested medication . . .

June 2015 Vol. 10 No. 6

Author: Julie Worley, PhD, FNP, PMHNP

Prescription substance use disorders (SUDs) have a serious impact on society. In 2013, 6.5 million adults admitted to illicit use of prescription medications. The annual cost of prescription SUDs is estimated at $72 billion. Additionally, annual deaths from opioid overdoses have quadrupled from 1999 to 2011 and nearly surpass . . .

May 2015 Vol. 10 No. 5

Author: Pamela Anderson, MSN, RN, APRN-BC, CCRN, and Terri Townsend, MA, RN, CCRN-CMC, CVRN-BC

Mistakes involving medications are among the most common healthcare errors. Medication errors lengthen hospital stays, increase inpatient expenses, and lead to more than 7,000 deaths annually in the United States. Each error costs an estimated $2,000 to $8,750. An error can happen in the home or a . . .

March 2015 Vol. 10 No. 3

Author: Janice Foust, PhD, RN, and Gretchen Kilbourne, PhD(c), RN

For chronically ill older adults who take multiple medications, a hospital stay can result in various medication-related changes.

Nurses administer their medications to them.
Their medication schedules may be altered due to hospital policy.
Specific drugs they receive may change depending on the hospital formulary.
Medication dosages and frequencies . . .

July 2014 Vol. 9 No. 7

Author: Rose O. Sherman, EdD, RN, NEA-BC, FAAN

On June 27, the U.S. Food and Drug Administration (FDA) approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Read more . . .

July 2014 Vol. 9 No. 7

Author: Rose O. Sherman, EdD, RN, NEA-BC, FAAN

On July 3, the U.S. Food and Drug Administration (FDA) approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma, a rare and fast-growing type of non-Hodgkin lymphoma. Read more . . .

July 2014 Vol. 9 No. 7

Author: Rose O. Sherman, EdD, RN, NEA-BC, FAAN

On July 16, the U.S. Food and Drug Administration (FDA) approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema.
Read more . . .

July 2014 Vol. 9 No. 7

Author: Rose O. Sherman, EdD, RN, NEA-BC, FAAN

In patients with a traumatic brain injury (TBI), the administration of the hormone erythropoietin (EPO) or maintaining a higher hemoglobin (Hgb) concentration through blood transfusion did not improve neurological outcome at 6 months, according to a study in JAMA. Transfusing at higher hemoglobin concentrations was associated with a higher risk . . .

June 2014 Vol. 9 No. 6

Author: Cindy Lefton, PhD, RN

On June 20, the U.S. Food and Drug Administration (FDA) approved Sivextro (tedizolid phosphate) to treat patients with acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus. Read more . . .

June 2014 Vol. 9 No. 6

Author: Cindy Lefton, PhD, RN

According to a study in JAMA, adding thrombolytics to conventional approaches when treating patients with sudden-onset pulmonary embolism is associated with 47% fewer deaths than using standard anticoagulant medications alone. Read more and read the study abstract . . .